A NEW CANCER TREATMENT CONCEIVED TO DO WHAT NO OTHER CANCER TREATMENTS CAN

Nothing is better than numbers! ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ [Unsubscribe]( We're excited to announce a groundbreaking opportunity in the fight against cancer. Starpax has launched a [Regulation A capital raise]( to fuel our pioneering clinical trials, aiming to revolutionize cancer treatment and offer hope to millions worldwide. (By clicking the link above, you are opting in to receive emails from this advertiser. You are also agreeing to the terms of our privacy policy. [Unsubscribe at any time]( Current cancer treatments struggle to reach 90% of the tumor volume. Antibodies, nanocarriers, precision targeting medicine, and even immune cells, don’t reach more than 10% of the tumor volume. Join us in our mission to change the way we treat cancer. Here's why you should consider investing in Starpax’s patented technology: The future of cancer treatment is here: Starpax's cutting-edge technology features Starpax Living self-propelled MagnetodronesTM, which are sensitive to special magnetic fields and carry drugs on their surface to the tumor volume. Additionally, the PolarTrak® machine generates magnetic fields that control the trajectory of the Magnetodrones™ in 3D, forcing the drugs to spread throughout the tumor volume. Cutting-edge technology: The Living Magnetodrones, guided by the PolarTrak’s artificial intelligence, are injected directly into the tumor. They are forced to spread across the tumor, reaching hypoxic zones. Preclinical trials have demonstrated a 100% remission rate in extremely aggressive tumors without any side effects observed. Reduced risk, accelerated progress: Starpax minimizes trial risks and accelerates approvals with our FDA-approved anti-cancer molecules that can target six common cancers simultaneously. We meet the criteria for the FDA Fast Track Program and Health Canada accelerated review standards, which will ensure swift progress Scalable business model: Partnering with top U.S. firms, Starpax plans rapid deployment of 25 treatment centers within seven years, with forecasted EBITDA, reaching $12 billion annually upon FDA approval. Together, we can create a future where cancer treatment is more effective, safe, and accessible. Invest in Starpax today and be part of this transformative journey. [Invest Now]( (By clicking the link above, you are opting in to receive emails from this advertiser. You are also agreeing to the terms of our privacy policy. [Unsubscribe at any time]( The Starpax Team info@starpaxbiopharma.com --------------------------------------------------------------- This is a PAID ADVERTISEMENT provided to the subscribers of Daily Options Signals Free Newsletter. Although we have sent you this email, Daily Options Signals and StockEarnings does not specifically endorse this product nor is it responsible for the content of this advertisement. Furthermore, we make no guarantee or warranty about what is advertised above. Your privacy is very important to us. If you no longer wish to receive email from DailyOptionsSignals.com, please click [Unsubscribe]( . StockEarnings, Inc 33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA W: 877.6.STOCKS StockEarnings.com [Today's Bonus Content: (NASDAQ:PROP) Is On Our Radar!]( [Please read full disclosure](